Serotonin hypothesis of autism: implications for selective serotonin reuptake inhibitor use during pregnancy.
The 2013 "inconclusive" call on prenatal SSRIs and autism was nudged toward "small real risk" by the 2014 registry study.
01Research in Context
What this study did
Fahmie et al. (2013) looked at every paper they could find on moms taking SSRI antidepressants while pregnant. They wanted to know if the pills raise the chance of autism in the baby.
They read studies, counted results, and wrote a narrative review. No new lab work was done.
What they found
The team said the evidence is still murky. Most studies showed no extra autism risk, but one study saw a small bump when moms took the drug in the first three months.
In short: we cannot yet say the medicines cause autism, but we cannot rule it out either.
How this fits with other research
Danitz et al. (2014) came next. Their big registry study found a small but real rise in autism odds after SSRI exposure. This updates the 2013 "we are not sure" verdict and nudges the field toward "small effect, but worth talking about."
Schneider et al. (2006) helps explain why scientists worry at all. They showed that many kids with autism already have high serotonin levels, giving a biological reason to look at serotonin-changing drugs.
Marí-Bauset et al. (2022) looked at other chemicals instead of SSRIs. They also found weak links, reminding us that many prenatal exposures are hard to pin down.
Why it matters
When you talk with expectant moms who take antidepressants, share the latest numbers. Tell them the risk looks small but is no longer zero. Weigh that against the large risk of untreated depression. Document the chat and stay alert for new data.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Add a one-page parent handout that lists SSRI risk as "small but now documented" and urges moms to keep taking meds until they talk with their doctor.
02At a glance
03Original abstract
Serotonin, a neurotransmitter found throughout the brain and body, has long been of interest in autism. Repeated findings of elevated platelet serotonin levels in approximately one third of children with autism has led some to believe that dysfunctional serotonin signaling may be a causal mechanism for the disorder. Because serotonin is critical to fetal brain development, concerns have arisen regarding prenatal exposure to substances that manipulate serotonin levels, such as selective serotonin reuptake inhibitors (SSRIs). This review examines evidence regarding the serotonin system and autism spectrum disorders (ASD), as well as what the literature has reported thus far on developmental effects of prenatal exposure to SSRIs. Possible mechanisms by which SSRIs could affect the fetus during pregnancy and clinical implications are also discussed. Though the majority of studies conducted in infants and children suggest prenatal exposure to SSRIs does not affect neurodevelopment, interpretation must be tempered given small sample sizes. The only published study that focused on prenatal SSRI exposure and ASD found an increased risk with exposure to SSRIs, especially during the first trimester. Obstacles that will be faced in future research are isolating medication effects from maternal depression and, given the infrequent occurrence of exposure and outcome, obtaining an adequate sample size. Whether serotonin is an etiologic factor in ASD, and what it points to as a marker for subgrouping, remains unclear. Understanding how the development of ASD might be affected by prenatal factors that influence serotonin levels, such as SSRIs, could identify modifiable targets for prevention.
Autism research : official journal of the International Society for Autism Research, 2013 · doi:10.1002/aur.1288